It is possible that alpha-1-antitrypsin could serve as a novel serum biomarker for a rapid, specific, and reliable prognostic tool of disease severity associated with organ damage in SLE patients via the process of complementary and inflammatory activations. This evidence concerns the gene SERPINA1 and systemic lupus erythematosus.